Brooks Laboratories Limited
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and d… Read more
Brooks Laboratories Limited (BROOKS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.003x
Based on the latest financial reports, Brooks Laboratories Limited (BROOKS) has a cash flow conversion efficiency ratio of 0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹3.19 Million) by net assets (₹1.16 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Brooks Laboratories Limited - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Brooks Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Brooks Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Brooks Laboratories Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MCKESSON
MU:MCK
|
-0.795x |
|
PESTECH International Bhd
KLSE:5219
|
-0.177x |
|
Ingram Micro Bilisim Sistemleri A.S.
IS:INGRM
|
0.002x |
|
Magle Chemoswed Holding Ab
ST:MAGLE
|
-0.092x |
|
Mangal Credit and Fincorp Limited
NSE:MANCREDIT
|
N/A |
|
Bonk, Inc.
NASDAQ:BNKK
|
-0.169x |
|
DAP Corporation
KQ:066900
|
-0.155x |
|
SINTX Technologies Inc
NASDAQ:SINT
|
-0.619x |
Annual Cash Flow Conversion Efficiency for Brooks Laboratories Limited (2007–2025)
The table below shows the annual cash flow conversion efficiency of Brooks Laboratories Limited from 2007 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹981.04 Million | ₹17.62 Million | 0.018x | +112.17% |
| 2024-03-31 | ₹655.85 Million | ₹-96.81 Million | -0.148x | +24.67% |
| 2023-03-31 | ₹739.53 Million | ₹-144.91 Million | -0.196x | +29.70% |
| 2022-03-31 | ₹1.34 Billion | ₹-374.41 Million | -0.279x | -594.81% |
| 2021-03-31 | ₹791.48 Million | ₹44.59 Million | 0.056x | +159.05% |
| 2020-03-31 | ₹984.16 Million | ₹-93.89 Million | -0.095x | -98.66% |
| 2019-03-31 | ₹1.05 Billion | ₹-50.49 Million | -0.048x | +11.07% |
| 2018-03-31 | ₹1.14 Billion | ₹-61.81 Million | -0.054x | -169.74% |
| 2017-03-31 | ₹1.24 Billion | ₹96.01 Million | 0.077x | +16.39% |
| 2016-03-31 | ₹1.22 Billion | ₹81.19 Million | 0.067x | +248.09% |
| 2015-03-31 | ₹1.11 Billion | ₹21.29 Million | 0.019x | -81.66% |
| 2014-03-31 | ₹1.12 Billion | ₹116.98 Million | 0.104x | +103.74% |
| 2013-03-31 | ₹1.05 Billion | ₹53.90 Million | 0.051x | +361.70% |
| 2012-03-31 | ₹912.63 Million | ₹-17.83 Million | -0.020x | -109.59% |
| 2011-03-31 | ₹194.27 Million | ₹39.59 Million | 0.204x | -51.15% |
| 2010-03-31 | ₹136.42 Million | ₹56.91 Million | 0.417x | +144.20% |
| 2009-03-31 | ₹85.37 Million | ₹14.58 Million | 0.171x | -58.33% |
| 2008-03-31 | ₹49.11 Million | ₹20.13 Million | 0.410x | +565.61% |
| 2007-03-31 | ₹17.58 Million | ₹1.08 Million | 0.062x | -- |